Certara (NASDAQ:CERT) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of Certara (NASDAQ:CERT) from a buy rating to a hold rating in a report released on Sunday.

Several other equities research analysts also recently weighed in on CERT. Stephens decreased their price target on shares of Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Morgan Stanley cut their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, December 18th. BMO Capital Markets started coverage on Certara in a report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price objective for the company. Finally, Leerink Partners raised Certara from a “market perform” rating to an “outperform” rating and set a $13.00 target price on the stock in a research report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.82.

Certara Price Performance

Shares of CERT opened at $6.62 on Friday. The firm has a market cap of $1.05 billion, a PE ratio of 94.57 and a beta of 1.47. Certara has a 52-week low of $6.45 and a 52-week high of $15.69. The business’s 50 day moving average price is $8.82 and its two-hundred day moving average price is $10.14. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CERT. Northwestern Mutual Wealth Management Co. increased its holdings in Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares during the last quarter. First Horizon Corp purchased a new position in shares of Certara in the third quarter worth about $30,000. Versant Capital Management Inc raised its position in shares of Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares during the period. Osaic Holdings Inc. raised its position in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new position in Certara in the 2nd quarter worth approximately $59,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.